Incidence of typhoid fever in Burkina Faso, Democratic Republic of the Congo, Ethiopia, Ghana, Madagascar, and Nigeria (the Severe Typhoid in Africa programme): a population-based study.

Autor:	Marks F; International Vaccine Institute, Seoul, South Korea; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK; Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar. Electronic address: fmarks@ivi.int., Im J; International Vaccine Institute, Seoul, South Korea., Park SE; International Vaccine Institute, Seoul, South Korea; Yonsei University Graduate School of Public Health, Seoul, South Korea; Yonsei University Graduate School of Public Health, Seoul, South Korea., Pak GD; International Vaccine Institute, Seoul, South Korea., Jeon HJ; International Vaccine Institute, Seoul, South Korea; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar., Wandji Nana LR; Institut Supérieur des Sciences de la Population, Ouagadougou, Burkina Faso., Phoba MF; Department of Microbiology, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo; Department of Medical Biology, Microbiology Service, University Teaching Hospital of Kinshasa, University of Kinshasa, Kinshasa, Democratic Republic of the Congo., Mbuyi-Kalonji L; Department of Microbiology, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo; Department of Medical Biology, Microbiology Service, University Teaching Hospital of Kinshasa, University of Kinshasa, Kinshasa, Democratic Republic of the Congo., Mogeni OD; International Vaccine Institute, Seoul, South Korea., Yeshitela B; Armauer Hansen Research Institute, Addis Ababa, Ethiopia., Panzner U; International Vaccine Institute, Seoul, South Korea., Cruz Espinoza LM; International Vaccine Institute, Seoul, South Korea., Beyene T; Armauer Hansen Research Institute, Addis Ababa, Ethiopia., Owusu-Ansah M; School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana., Twumasi-Ankrah S; School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; Department of Statistics and Actuarial Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana., Yeshambaw M; Armauer Hansen Research Institute, Addis Ababa, Ethiopia., Alemu A; Department of Medicine, University of Ibadan, Ibadan, Nigeria., Adewusi OJ; College of Medicine, University of Ibadan, Ibadan, Nigeria., Adekanmbi O; Department of Medicine, University of Ibadan, Ibadan, Nigeria; Department of Community Medicine, University College Hospital, Ibadan, Nigeria., Higginson E; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK., Adepoju A; Department of Paediatrics, University of Ibadan, Ibadan, Nigeria; Department of Community Medicine, University College Hospital, Ibadan, Nigeria., Agbi S; Department of Medicine, University of Ibadan, Ibadan, Nigeria., Cakpo EG; Institut Supérieur des Sciences de la Population, Ouagadougou, Burkina Faso., Ogunleye VO; Department of Community Medicine, University College Hospital, Ibadan, Nigeria., Tunda GN; Department of Microbiology, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo; Faculty of Medicine, Congo Protestant University, Kinshasa, Democratic Republic of the Congo., Ikhimiukor OO; Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria., Mbuyamba J; Department of Microbiology, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo; Department of Medical Biology, Microbiology Service, University Teaching Hospital of Kinshasa, University of Kinshasa, Kinshasa, Democratic Republic of the Congo., Toy T; International Vaccine Institute, Seoul, South Korea., Agyapong FO; Department of Clinical Microbiology, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana., Osei I; Medical Research Council Unit, The Gambia at London School of Hygiene & Tropical Medicine, Banjul, The Gambia; Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK., Amuasi J; School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; Bernhard Nocht Institute of Tropical Medicine, Hamburg, Germany; Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR), Kumasi, Ghana., Razafindrabe TJL; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar., Raminosoa TM; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar., Nyirenda G; International Vaccine Institute, Seoul, South Korea., Randriamampionona N; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar., Seo HW; International Vaccine Institute, Seoul, South Korea., Seo H; International Vaccine Institute, Seoul, South Korea., Siribie M; International Vaccine Institute, Seoul, South Korea., Carey ME; Department of Infection Biology, London School of Hygiene & Tropical Medicine, London, UK; International AIDS Vaccine Initiative, Chelsea & Westminster Hospital, London, UK., Owusu M; Department of Medical Diagnostics, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; Centre for Health System Strengthening (CfHSS), Kumasi, Ghana; Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR), Kumasi, Ghana., Meyer CG; Institute of Tropical Medicine, Eberhard-Karls University Tübingen, Tübingen, Germany; Duy Tan University, Da Nang, Viet Nam., Rakotozandrindrainy N; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar., Sarpong N; School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana., Razafindrakalia M; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar., Razafimanantsoa R; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar., Ouedraogo M; Hôpital Protestant Schiphra, Ouagadougou, Burkina Faso., Kim YJ; International Vaccine Institute, Seoul, South Korea., Lee J; International Vaccine Institute, Seoul, South Korea; Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia., Zellweger RM; International Vaccine Institute, Seoul, South Korea., Kang SSY; International Vaccine Institute, Seoul, South Korea., Park JY; International Vaccine Institute, Seoul, South Korea; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK., Crump JA; Centre for International Health, University of Otago, Dunedin, New Zealand., Hardy L; Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium., Jacobs J; Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven Belgium., Garrett DO; Sabin Vaccine Institute, Washington, DC, USA., Andrews JR; Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA., Poudyal N; International Vaccine Institute, Seoul, South Korea., Kim DR; International Vaccine Institute, Seoul, South Korea., Clemens JD; International Vaccine Institute, Seoul, South Korea; Jonathan and Karin Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, USA., Baker SG; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK., Kim JH; International Vaccine Institute, Seoul, South Korea; Department of Life Sciences, College of Natural Sciences, Seoul National University, Seoul, South Korea., Dougan G; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK., Sugimoto JD; International Vaccine Institute, Seoul, South Korea; Epidemiologic Research and Information Center, Cooperative Studies Program, Office of Research and Development, United States Department of Veterans Affairs, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle WA USA., Van Puyvelde S; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerpen, Belgium., Kehinde A; Department of Medical Microbiology and Parasitology, College of Medicine, University of Ibadan, Ibadan, Nigeria., Popoola OA; Department of Community Medicine, University College Hospital, Ibadan, Nigeria; Department of Community Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria., Mogasale V; International Vaccine Institute, Seoul, South Korea., Breiman RF; Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA; Infectious Diseases and Oncology Research Institute, University of the Witwatersrand, Johannesburg, South Africa., MacWright WR; Public Health Surveillance Group, Princeton, NJ, USA., Aseffa A; Armauer Hansen Research Institute, Addis Ababa, Ethiopia., Tadesse BT; International Vaccine Institute, Seoul, South Korea; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden; Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia., Haselbeck A; International Vaccine Institute, Seoul, South Korea., Adu-Sarkodie Y; School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; Department of Clinical Microbiology, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana., Teferi M; Armauer Hansen Research Institute, Addis Ababa, Ethiopia., Bassiahi AS; Institut Supérieur des Sciences de la Population, Ouagadougou, Burkina Faso., Okeke IN; Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria., Lunguya-Metila O; Department of Microbiology, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo; Department of Medical Biology, Microbiology Service, University Teaching Hospital of Kinshasa, University of Kinshasa, Kinshasa, Democratic Republic of the Congo., Owusu-Dabo E; School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana., Rakotozandrindrainy R; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar.
Jazyk:	angličtina
Zdroj:	The Lancet. Global health [Lancet Glob Health] 2024 Apr; Vol. 12 (4), pp. e599-e610.
DOI:	10.1016/S2214-109X(24)00007-X
Abstrakt:	Background: Typhoid Fever remains a major cause of morbidity and mortality in low-income settings. The Severe Typhoid in Africa programme was designed to address regional gaps in typhoid burden data and identify populations eligible for interventions using novel typhoid conjugate vaccines. Methods: A hybrid design, hospital-based prospective surveillance with population-based health-care utilisation surveys, was implemented in six countries in sub-Saharan Africa. Patients presenting with fever (≥37·5°C axillary or ≥38·0°C tympanic) or reporting fever for three consecutive days within the previous 7 days were invited to participate. Typhoid fever was ascertained by culture of blood collected upon enrolment. Disease incidence at the population level was estimated using a Bayesian mixture model. Findings: 27 866 (33·8%) of 82 491 participants who met inclusion criteria were recruited. Blood cultures were performed for 27 544 (98·8%) of enrolled participants. Clinically significant organisms were detected in 2136 (7·7%) of these cultures, and 346 (16·2%) Salmonella enterica serovar Typhi were isolated. The overall adjusted incidence per 100 000 person-years of observation was highest in Kavuaya and Nkandu 1, Democratic Republic of the Congo (315, 95% credible interval 254-390). Overall, 46 (16·4%) of 280 tested isolates showed ciprofloxacin non-susceptibility. Interpretation: High disease incidence (ie, >100 per 100 000 person-years of observation) recorded in four countries, the prevalence of typhoid hospitalisations and complicated disease, and the threat of resistant typhoid strains strengthen the need for rapid dispatch and implementation of effective typhoid conjugate vaccines along with measures designed to improve clean water, sanitation, and hygiene practices. Funding: The Bill & Melinda Gates Foundation. Competing Interests: Declaration of interests We declare no competing interests. (Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu